Noxopharm Achieves Milestone in Autoimmune Drug Development with HERACLES Trial Completion
Noxopharm Ltd. has successfully completed the HERACLES clinical trial for its autoimmune drug candidate SOF-SKN™, confirming its safety and tolerability at the highest dose. This milestone positions the company to explore SOF-SKN’s potential in treating autoimmune-related skin diseases. The global market for cutaneous lupus erythematosus, a target condition, is valued at over US$3.3 billion, indicating significant commercial potential for Noxopharm's innovations. Noxopharm is a clinical-stage biotech firm focused on developing novel treatments for cancer and inflammation.
Tip Ranks·